Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to assess the efficacy and safety of repeated administration of adalimumab in adult Japanese subjects with moderate to severe chronic plaque psoriasis.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Collaborator: Eisai Limited
• Treatments: Adalimumab; Antibodies; Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• Subject was age 20 or older and in good health (Investigator discretion) with a recent stable medical history.

• Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis

Exclusion Criteria:

• Subject had previously received anti-TNF therapy.

• Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVA, UVB or PUVA phototherapy

• Subject is taking or requires oral or injectable corticosteroids

• Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study

• Female subject who is pregnant or breast-feeding or considering becoming pregnant